Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Research

Health service security of patients with 8 certain rare diseases: evidence from China’s national system for health service utilization of patients with healthcare insurance

Authors: Rui Min, Xiaoyan Zhang, Pengqian Fang, Biyan Wang, He Wang

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Rare diseases are one of the major challenges in the era of precision medicine and reflect the social security level of minority groups. This study aimed to investigate healthcare service utilization and health security of patients with rare diseases in China.

Methods

From 29 provinces of Mainland China, 7,747 visits with eight common rare diseases who were linked to the national insurance database between 2014 and 2016 were selected as the study population, whose demographic and healthcare service information was collected from China’s national monitoring system for health service utilization of patients with healthcare insurance. Univariate analysis was performed to describe the basic statement of healthcare service, such as visit type, institution type, length of stay, healthcare insurance utilization, and the results of disease burden for different groups and its factors were analyzed by multivariate analysis.

Results

Medical treatment from general tertiary hospitals was sought by 61.4% of the patients with rare diseases. Of the total treatment cost (TTC) of 40.18 million Chinese Yuan, 63.3% was paid by basic health insurance, and 54.2% of the medical cost resulted from medicine expenditure. Demography, geography and social-economic factors, security level, and health institution situation had an effect on the TTC. The correlations between these factors and TTC were different for outpatients and inpatients. Reimbursement rate had the highest effect on inpatients’ TTC. Basic insurance was effective for providing support for patients with rare diseases that involved high costs; however, the coverage was limited.

Conclusions

Healthcare insurance is an effective safeguard for patients with rare diseases; however, affordable and accessible treatment is still lacking for such patients. There remains a need to further improve the diagnostic and treatment technology for rare diseases and expertise among doctors, as well as the security level of healthcare policies.
Appendix
Available only for authorised users
Literature
1.
2.
3.
World Health Organization (WHO). Coming together to combat rare diseases. B World Health Organ. 2012;90(6):401–76.
4.
5.
Song P, He J, Li F, Jin C. Innovative measures to combat rare diseases in China: the national rare diseases registry system, larger-scale clinical cohort studies, and studies in combination with precision medicine research. Intractable Rare Dis Res. 2017;6(1):1–5.PubMedPubMedCentralCrossRef
6.
Zhang YJ, Guo JJ, Wang JB. Rare diseases, orphan drugs, and the legislation in China. Value Health. 2010;13(7):A533.CrossRef
7.
Dong Dong EA. Annual report on rare diseases in China, 2018. In: Illness Chanllenge Foundation; Hong Kong Baptist University; Huazhong University of Science and Technology; 2018.
8.
Mengning L, Yirong Y, Feng C. Analysis of problems and countermeasures of rare diseases medical analysis of problems and countermeasures of rare diseases medical Insurance in the International Environment. Chin J Med Guide. 2017;19(8):846–51.
9.
10.
Lin H, Long E, Chen W, Liu Y. Documenting rare disease data in China. Science. 2015;349(6252):1064.PubMedCrossRef
11.
12.
Saviano M, Barile S, Caputo F, Lettieri M, Zanda S. From rare to neglected diseases: a sustainable and inclusive healthcare perspective for reframing the orphan drugs issue. Sustain-Basel. 2019;11(5):1289.CrossRef
13.
Wang J, Guo JJ, Yang L, Zhang Y, Sun Z, Zhang Y. Rare diseases and legislation in China. Lancet. 2010;375(9716):708–9.PubMedCrossRef
14.
15.
China National Health Commission (NHC). China health statistical yearbook. Beijing: China union medical University Press; 2017.
16.
Lilin L, Langenbrunner JC. The long march to universal coverage: lessons from China. In: Universal Health Coverage Studies Series (UNICO), vol. 9. Washington DC: World Bank; 2013.
17.
Hongmei Z, Haicheng Z. DRGs and public hospital reform. China Hosp. 2010;14(1):20–1.
18.
19.
20.
Bin W, Renxia L, Jianping C, Al E. The Current Status and Strategies of Medical Security of Patients with Rare Diseases in Fujian. Chin Health Econ. 2017;36(3):37–9.
21.
Zhang Y, Zhang Y, Wang J, Guo JJ. Rare diseases, orphan drugs, and the legislation in China. Pharmacoepidem DR S. 2010;191:S257–8.
22.
Fang P, Pan Z, Zhang X, Bai X, Gong Y, Yin X. The effect of critical illness insurance in China. Medicine. 2018;97:e1136227.
23.
Feng S, Gong M, Zhang S. The national rare diseases registry system of China and the related cohort studies: vision and roadmap. Chin J Endocrinol Metab. 2016;32:977–82 (1000–-6699(2016)32:12<977:ZGGJHJ>2.0.TX;2-H12).
24.
25.
Gong S, Wang Y, Pan X, Zhang L, Huang R, Chen X, Hu J, Xu Y, Jin S. The availability and affordability of orphan drugs for rare diseases in China. Orphanet J Rare Dis. 2016;11:20.PubMedPubMedCentralCrossRef
26.
Xiaoping L, Tianyou W. The future direction of rare disease in China: from the current diagnosis and treatment situation of Gaucher disease. Chin J Pediatr. 2015;53(4):254–5.
27.
Tang Q, Song P, Mei L, Xu L, Tang W. Epidemiological research, scientific research, and applied research on rare diseases in China: current challenges and prospects for the future. Expert Opin Orphan D. 2017;5(1):37–44.CrossRef
28.
Guan Y, Dai G, Su Y, Zhang F. Comparison of Research Support for Rare Diseases and Orphan Drugs Innovation in China and the United States. Chin Pharm J. 2016;51:1152–6. (1001–2494(2016)51:13<1152:ZMHJBH>2.0.TX;2-O13).
29.
Ni X, Shi T. The challenge and promise of rare disease diagnosis in China. Sci China Life Sci. 2017;60(7):681–5.PubMedCrossRef
30.
Rui M, Dingguo L, Xue Z, Lin H. Opportunities and challenges in the prevention and treatment of rare diseases in China. Chin J Evid Based Pediatr. 2011;6:81–2.
31.
China Healthcare Insurance Research Association (CHIRA). National basic health insurance utility: annual investigation report on the utilization of medical devices, medicine and treatment (2016), vol. 1. Beijing: China Healthcare Insurance Research Association; 2016. p. 286–91.
32.
33.
34.
35.
36.
Xiaoyang Y, Mengjie W, Fangping C. Interpretation of Chinese and international guidelines of acute promyelocytic leukemia. J Leuk Lymphoma. 2016;25(10):618–22.
37.
HHS, NIH, GARD, NCATS. Find rare disease by category in GARD (genetic and rare disease information center), vol. 2018; 2017.
38.
39.
Aili Myasthenia Gravis Care Center, Hong Kong Baptist University. Annual Survival status tracking report of myasthenia gravis patients (2016). Beijing: MG-Care- Center, Aili Myasthenia Gravis Care University, Hong Kong Baptist; 2016.
40.
Nelson J, Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101(3):355–8.PubMedCrossRef
41.
National Institute of Neurological Stroke (NINDS). Mucopolysaccharidoses Face Sheet, vol. 2018; 2017.
42.
Poorthuis BJHM, Wevers RA, Kleijer WJ, Groener JEM, Jong JGND, Weely SV, Niezen-Koning KE, Diggelen OPV. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet. 1999;105(1–2):151–6.PubMedCrossRef
43.
Modrego PJ, Pina MA. Trends in prevalence and incidence of multiple sclerosis in Bajo Aragon, Spain. J Neurol Sci. 2003;216(1):89–93.PubMedCrossRef
44.
Al HN, Christodoulou J. Phenylketonuria: a review of current and future treatments. Transl Pediatr. 2015;4(4):304.
45.
46.
Burns LR, Liu GG. China's healthcare system and reform. Cambridgeshire: Cambridge University Press; 2017.
47.
FANG P, editor. Green book of health reform and development: annual report 2016, special issue for reform and development in healthcare insurance system. Beijing: People’s Press; 2017.
48.
World Health Organization (WHO). Health financing strategy for the Asia Pacific region (2010–2015). Geneva: WHO Press; 2009.
49.
Lei Z. Critical illness insurance and catastrophic health expenditure. Economist. 2015;12:52–3.
50.
Shanchang X. Critical illness insurance: an important link in improving the health care system. Macroecon Manag. 2013;3:31–2.
51.
52.
Fullman N, Yearwood J, Abay SM, Abbafati C, Abd-Allah F, Abdela J, Abdelalim A, Abebe Z, Abebo TA, Aboyans V, et al. Measuring performance on the healthcare access and quality index for 195 countries and territories and selected subnational locations: a systematic analysis from the global burden of disease study 2016. Lancet. 2018;391(10136):2236–71.CrossRef
53.
Liming C, Meng J, Zhengyang H, Zimeng G, Dingguo L. Study on the status and countermeasures of rare disease group. Med Philos. 2016;37(11b):3–6.
54.
55.
56.
57.
Ying L. Policy Recommendations Regarding Rare Diseases in China - An Analysis Based on a survey of living conditions of the people with rare diseases. China Soft Sci. 2014;278(2):77–89.
58.
Ren Q, Wang J. Network established to collaborate on diagnosis and treatment of rare diseases in China: a strategic alliance backed by tiered healthcare is the key to the future. Intractable Rare Dis Res. 2019;8(1):78–9.PubMedPubMedCentralCrossRef
59.
Huang R, Shao W. China rare disease drug accessibility report 2019 (Chinese version only). Beijing: Chinese Organization for Rare Disorders; 2019. p. 13.
60.
ASKCI CONSULTING. 2018 Annual report on the structure of China's medicine market. ASKCI Consulting: Shenzhen; 2018.
Metadata
Title
Health service security of patients with 8 certain rare diseases: evidence from China’s national system for health service utilization of patients with healthcare insurance
Authors
Rui Min
Xiaoyan Zhang
Pengqian Fang
Biyan Wang
He Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1165-7

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue

Research

Reducing complexity: explaining inborn errors of metabolism and their treatment to children and adolescents

Research

An algorithm as a diagnostic tool for central ocular motor disorders, also to diagnose rare disorders

Research

Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool

Research

Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada

Letter to the Editor

Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group

Research

Primary hypertrophic osteoarthropathy related gastrointestinal complication has distinctive clinical and pathological characteristics: two cases report and review of the literature